How Is Incyte’s Stock Performance Compared to Other Biotech Stocks?

0
101
Incyte Corp_ office sign-by Bo Shen via iStock

Based in Wilmington, Delaware, Incyte Corporation (INCY) is a global biopharmaceutical company that discovers, develops, and commercializes innovative treatments for cancer, blood disorders, and immune-mediated diseases.

The company’s marketed therapies include JAKAFI for blood cancer, ICLUSIG for leukemia, PEMAZYRE for bile-duct cancer, MONJUVI/MINJUVI for lymphoma, and NIKTIMVO for fibrotic disease. Incyte is also advancing a growing clinical pipeline to treat additional cancers, myeloproliferative neoplasms, inflammatory diseases, and rare disorders.

More News from Barchart

These efforts have helped the company reach a market cap of approximately $25.3 billion, putting it above the $10 billion threshold commonly used to classify large-cap stocks.

The stock is currently trading…

Read more…

LEAVE A REPLY

Please enter your comment!
Please enter your name here